Company research
BRUKER CORP
CIK 1109354Updated Sep 26, 2026
Name history
BRUKER BIOSCIENCES CORP · through Feb 27, 2008BRUKER DALTONICS INC · through Jul 2, 2003
BRKR price & chart
Loading TradingView…
NASDAQ:BRKR on TradingView ↗About the company
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in specialty diagnostics, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, clinical microbiology and molecular diagnostics, as well as in the semiconductor industry. For more information, please visit www.bruker.com.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 6,241,400,000Source | 5,806,700,000Source | 4,249,900,000Source | 3,611,800,000Source |
| Property, Plant and Equipment, NetUSD | 744,800,000Source | 669,300,000Source | 599,700,000Source | 487,000,000Source |
| GoodwillUSD | 1,547,700,000Source | 1,507,300,000Source | 582,600,000Source | 457,600,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 899,600,000Source | 912,500,000Source | 330,500,000Source | 270,900,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 298,800,000Source | 183,400,000Source | 488,300,000Source | 645,500,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 544,900,000Source | 565,500,000Source | 492,000,000Source | 472,700,000Source |
| Inventory, NetUSD | 1,094,600,000Source | 1,067,800,000Source | 968,300,000Source | 800,100,000Source |
| Assets, CurrentUSD | 2,212,500,000Source | 2,053,200,000Source | 2,164,200,000Source | 2,113,200,000Source |
| Operating Lease, Right-of-Use AssetUSD | 165,800,000Source | 145,500,000Source | 91,700,000Source | 51,200,000Source |
| Other Assets, NoncurrentUSD | 249,300,000Source | 232,700,000Source | 184,000,000Source | 155,100,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 3,731,100,000Source | 3,991,500,000Source | 2,836,600,000Source | — |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 1,800,000Source | — | — | — |
| Retained Earnings (Accumulated Deficit)USD | 2,361,800,000Source | 2,406,700,000Source | 2,323,800,000Source | 1,926,000,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -79,500,000Source | -103,500,000Source | 6,000,000Source | 14,800,000Source |
| Stockholders' Equity Attributable to ParentUSD | 2,456,500,000Source | 1,781,200,000Source | 1,377,200,000Source | 1,113,800,000Source |
| Additional Paid in Capital, Common StockUSD | 1,414,600,000Source | 713,400,000Source | 282,900,000Source | 256,300,000Source |
| Liabilities and EquityUSD | 6,241,400,000Source | 5,806,700,000Source | 4,249,900,000Source | 3,611,800,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 1,279,200,000Source | 1,281,300,000Source | 1,202,100,000Source | 914,300,000Source |
| Operating Lease, Liability, CurrentUSD | 35,200,000Source | 32,100,000Source | 23,300,000Source | 16,400,000Source |
| Accounts Payable, CurrentUSD | 215,900,000Source | 234,100,000Source | 202,700,000Source | 178,400,000Source |
| Operating Lease, Liability, NoncurrentUSD | 138,600,000Source | 118,900,000Source | 74,800,000Source | 34,800,000Source |
| Deferred Income Tax Liabilities, NetUSD | 112,500,000Source | 118,500,000Source | 67,700,000Source | 62,300,000Source |
| Other Liabilities, NoncurrentUSD | 239,200,000Source | 311,000,000Source | 163,600,000Source | 166,200,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 17,000,000Source | 15,900,000Source | 17,400,000Source | 11,900,000Source |
| Additional Financial Items | ||||
| Deferred Revenue, CurrentUSD | — | 438,200,000Source | 400,000,000Source | — |
| Dividends Payable, CurrentUSD | 11,500,000Source | — | — | — |
| Long-term Debt, Excluding Current Maturities | — | — | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 1,852,500,000Source | 2,061,800,000Source | 1,160,300,000Source | 1,200,500,000Source |
| Redeemable Noncontrolling Interest, Equity, Carrying AmountUSD | 36,800,000Source | 18,100,000Source | 18,700,000Source | 6,100,000Source |
| Short-term InvestmentsUSD | — | — | — | 0Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -8,300,000Source | 113,800,000Source | 428,500,000Source | 298,500,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 220,300,000Source | 183,800,000Source | 114,900,000Source | 88,800,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 20,200,000Source | 25,300,000Source | 24,000,000Source | 27,700,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -54,200,000Source | 40,600,000Source | 900,000Source | 67,900,000Source |
| Increase (Decrease) in InventoriesUSD | -12,100,000Source | 69,800,000Source | 125,000,000Source | 137,900,000Source |
| Increase (Decrease) in Accounts PayableUSD | -37,500,000Source | 20,800,000Source | — | — |
| Deferred Income Tax Expense (Benefit)USD | -104,500,000Source | -63,800,000Source | -24,400,000Source | -14,800,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 134,100,000Source | 251,300,000Source | 350,100,000Source | 274,400,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 73,900,000Source | 1,599,600,000Source | 226,600,000Source | 182,300,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -196,500,000Source | -1,757,300,000Source | -326,000,000Source | -251,600,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | -4,800,000Source | — | — | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | 90,800,000Source | 115,300,000Source | 106,900,000Source | 129,200,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | 10,000,000Source | 0Source | 152,300,000Source | 263,100,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 135,100,000Source | 1,229,800,000Source | -193,400,000Source | -415,300,000Source |
| Payments of Ordinary Dividends, Common StockUSD | 22,800,000Source | 30,200,000Source | 29,400,000Source | 29,800,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | -8,300,000Source | — | — | — |
| Repayments of Long-term DebtUSD | 466,500,000Source | 135,400,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 116,400,000Source | -304,900,000Source | -157,100,000Source | -423,000,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 303,100,000Source | 186,700,000Source | 491,600,000Source | 648,700,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 71,000,000Source | 54,600,000Source | 33,700,000Source | 24,300,000Source |
| Income Taxes Paid, NetUSD | 222,500,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 43,700,000Source | -28,700,000Source | 12,200,000Source | -30,500,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 23,700,000Source | 21,700,000Source | 18,400,000Source | 15,700,000Source |
| Amortization of Intangible AssetsUSD | 121,200,000Source | 99,100,000Source | 47,100,000Source | 37,100,000Source |
| Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to SettlementUSD | -1,000,000Source | 0Source | 0Source | -300,000Source |
| DepreciationUSD | 99,100,000Source | 84,700,000Source | 67,800,000Source | 51,600,000Source |
| Dividends Payable, CurrentUSD | 11,500,000Source | — | — | — |
| Equity Method Investment, Other than Temporary ImpairmentUSD | 20,000,000Source | 24,600,000Source | 18,200,000Source | — |
| Equity Method Investment, Realized Gain (Loss) on DisposalUSD | — | 0Source | 6,800,000Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 11,600,000Source | 23,700,000Source | -13,300,000Source | -5,800,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | -4,600,000Source | 8,500,000Source | — |
| GoodwillUSD | 1,547,700,000Source | 1,507,300,000Source | 582,600,000Source | 457,600,000Source |
| Goodwill and Intangible Asset ImpairmentUSD | — | — | 0Source | — |
| Goodwill, Impairment LossUSD | 96,500,000Source | — | — | 3,100,000Source |
| Income Tax Expense (Benefit)USD | 29,300,000Source | 91,400,000Source | 117,700,000Source | 116,400,000Source |
| InterestExpenseNonoperatingUSD | 60,300,000Source | 47,900,000Source | — | — |
| Inventory Write-downUSD | 76,000,000Source | — | — | — |
| Investment Income, InterestUSD | 14,800,000Source | 9,300,000Source | 7,500,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -8,600,000Source | 113,100,000Source | 427,200,000Source | 296,600,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 300,000Source | 700,000Source | 1,300,000Source | 1,900,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -22,500,000Source | 113,100,000Source | 427,200,000Source | 296,600,000Source |
| Nonoperating Income (Expense)USD | -46,200,000Source | -46,200,000Source | -36,800,000Source | -18,800,000Source |
| Operating ExpensesUSD | 1,509,500,000Source | 1,396,400,000Source | 1,076,400,000Source | 873,000,000Source |
| Operating Lease, Impairment LossUSD | — | 1,500,000Source | 3,200,000Source | — |
| Other Nonoperating Income (Expense)USD | -46,200,000Source | -38,200,000Source | -36,800,000Source | — |
| Other Operating Income (Expense), NetUSD | -1,200,000Source | 0Source | 3,700,000Source | — |
| Payments of Financing CostsUSD | — | 5,500,000Source | 0Source | 0Source |
| Proceeds from Issuance of Common StockUSD | 7,900,000Source | 6,000,000Source | 9,500,000Source | 2,800,000Source |
| Proceeds from Issuance of Long-term DebtUSD | 3,500,000Source | 973,700,000Source | — | 0Source |
| Proceeds from Noncontrolling InterestsUSD | — | — | 5,000,000Source | — |
| Proceeds from (Payments to) Noncontrolling InterestsUSD | — | -14,700,000Source | 3,000,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 3,436,500,000Source | 3,366,400,000Source | 2,964,500,000Source | 2,530,700,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 946,500,000Source | 893,800,000Source | 729,400,000Source | 607,400,000Source |
| Operating Income (Loss)USD | 68,200,000Source | 253,100,000Source | 436,900,000Source | 432,700,000Source |
| Other Nonoperating Income (Expense)USD | -46,200,000Source | -38,200,000Source | -36,800,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 22,000,000Source | 206,900,000Source | 544,200,000Source | 413,900,000Source |
| Income Tax Expense (Benefit)USD | 29,300,000Source | 91,400,000Source | 117,700,000Source | 116,400,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 300,000Source | 700,000Source | 1,300,000Source | 1,900,000Source |
| Net Income (Loss) Attributable to ParentUSD | -8,600,000Source | 113,100,000Source | 427,200,000Source | 296,600,000Source |
| Earnings Per Share, BasicUSD per share | -0.15Source | 0.76Source | 2.92Source | 2Source |
| Earnings Per Share, DilutedUSD per share | -0.15Source | 0.76Source | 2.9Source | 1.99Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 151,800,000Source | 149Source | 146.4Source | 148.6Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 151,800,000Source | 149.5Source | 147.2Source | 149.4Source |
| Interest Expense (non-operating)USD | 60,300,000Source | 47,900,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 121,200,000Source | 99,100,000Source | 47,100,000Source | 37,100,000Source |
| Business Combination, Acquisition Related CostsUSD | 6,400,000Source | 54,900,000Source | 16,800,000Source | 19,300,000Source |
| Common Stock, Dividends, Per Share, DeclaredUSD per share | — | — | 0.2Source | 0.16Source |
| Current Income Tax Expense (Benefit)USD | 133,700,000Source | 155,200,000Source | 143,400,000Source | 127,400,000Source |
| Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to SettlementUSD | -1,000,000Source | 0Source | 0Source | -300,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 11,600,000Source | 23,700,000Source | -13,300,000Source | -5,800,000Source |
| Goodwill, Impairment LossUSD | 96,500,000Source | — | — | 3,100,000Source |
| Gross ProfitUSD | 1,577,700,000Source | 1,649,500,000Source | 1,513,300,000Source | 1,305,700,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -317,900,000Source | -250,200,000Source | 700,000Source | -13,300,000Source |
| Interest and Other IncomeUSD | — | — | — | 4,100,000Source |
| Interest ExpenseUSD | — | — | 16,400,000Source | 16,100,000Source |
| Interest Expense, DebtUSD | — | 47,900,000Source | 16,400,000Source | 16,100,000Source |
| Investment Income, InterestUSD | 14,800,000Source | 9,300,000Source | 7,500,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -22,500,000Source | 113,100,000Source | 427,200,000Source | 296,600,000Source |
| Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost ComponentUSD | -3,000,000Source | -1,300,000Source | 100,000Source | 1,000,000Source |
| Nonoperating Income (Expense)USD | -46,200,000Source | -46,200,000Source | -36,800,000Source | -18,800,000Source |
| Operating ExpensesUSD | 1,509,500,000Source | 1,396,400,000Source | 1,076,400,000Source | 873,000,000Source |
| Other Operating Income (Expense), NetUSD | -1,200,000Source | 0Source | 3,700,000Source | — |
| Preferred Stock Dividends and Other AdjustmentsUSD | 13,900,000Source | — | — | — |
| Research and Development ExpenseUSD | 395,200,000Source | 376,500,000Source | 294,800,000Source | 235,900,000Source |
Filing attachments
brkr-ex99_1.htm · 8-K · 2026-08-04
EX-99.1 2 brkr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Bruker Reports Second Quarter 2026 Financial Results • Q2-26 Bruker Scientific Instruments (BSI) bookings up 10% organically year-over-year (yoy), with BSI book-to-bill >1.0x • Q2-26 revenue of $838.5 million, up +5.2% yoy; up 2.8% organically, or +3.4% excluding tariff refunds • Q2-26 GAAP diluted loss per share of $(0.41); non-GAAP diluted earnings per share (EPS) $0.49 • Updating FY2026 guidance for currency and tax only: o Re…
Read attachment ↗brkr-ex99_1.htm · 8-K · 2026-05-06
EX-99.1 2 brkr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Bruker Reports First Quarter 2026 Financial Results • Q1 2026 revenues of $823.4 million, up 2.7% year-over-year (yoy), down 4.4% organically • Q1-26 GAAP diluted earnings per share (EPS) $0.02; non-GAAP diluted EPS $0.31 • Q1-26 Bruker Scientific Instruments (BSI) bookings up high-single digits % organically yoy; BSI book-to-bill ratio above 1.0x for 3rd consecutive quarter • Reconfirming previous FY2026 guidance: o Revenues of…
Read attachment ↗brkr-ex99_1.htm · 8-K · 2026-04-01
EX-99.1 2 brkr-ex99_1.htm EX-99.1 EX-99.1 Mr. Bernard currently serves as Chief Executive Officer of QIAGEN N.V. He joined QIAGEN in 2015 to lead its growing molecular diagnostics business and was named Chief Executive Officer in 2019. He has announced his intention to step down as CEO upon the appointment of a successor. Previously, Mr. Bernard held roles of increasing responsibility during 15 years with bioMérieux SA, including as Corporate Vice President for Global Commercial Operations…
Read attachment ↗brkr-ex99_1.htm · 8-K · 2026-02-12
EX-99.1 2 brkr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Bruker Reports Fourth Quarter and Full Year 2025 Financial Results • Q4-25 revenues of $977.2 million, flat year-over-year (yoy), down ~5% organically • Q4-25 GAAP diluted earnings per share (EPS) of $0.10; non-GAAP diluted EPS of $0.59 • FY25 revenues of $3.44 billion, up ~2% yoy, down ~4% organically • FY25 GAAP diluted loss per share of $(0.15); non-GAAP diluted EPS of $1.83 • Bruker initiates FY26 guidance: o Revenues of $3.…
Read attachment ↗brkr-ex99_1.htm · 8-K · 2025-12-09
EX-99.1 2 brkr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Bruker announces the addition of Diagnostics Industry leader Jack Phillips to its Board of Directors as of January 2026 BILLERICA, Massachusetts - December 8, 2025 - Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has added Jack J. Phillips to serve on its board of directors, effective as of January 1st, 2026. Mr. Phillips is a senior healthcare industry executive with over 30 years of leadership experien…
Read attachment ↗brkr-ex99_1.htm · 8-K · 2025-11-03
EX-99.1 2 brkr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Bruker Reports Third Quarter 2025 Financial Results • Q3 2025 revenues of $860.5 million, down 0.5% year-over-year (yoy), down 4.5% organically • Q3 2025 GAAP diluted loss per share $(0.41); non-GAAP diluted earnings per share (EPS) $0.45 • Updated FY2025 guidance: o Revenue $3.41 to $3.44 billion; reported growth of 1-2% yoy, organic decline of 4-5% o Non-GAAP EPS $1.85 to $1.90 BILLERICA, Massachusetts - November 3, 2025 - Br…
Read attachment ↗